Clinical Trials
8 trialsNCT04893486 2024-08-29
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
Palvella Therapeutics, Inc.
Phase 2 Completed
NCT03703310 2024-07-03
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Sol-Gel Technologies, Ltd.
Phase 3 Completed
NCT04416516 2024-04-10
Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor
Ascend Biopharmaceuticals Ltd
Phase 2 Completed
NCT02762084 2020-07-23
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
PellePharm, Inc.
Phase 2 Completed
NCT02828111 2019-01-08
BCC
PellePharm, Inc.
Phase 2 Completed
NCT02550678 2018-06-06
ASN-002-001
Ascend Biopharmaceuticals Ltd
Phase 1/2 Completed
NCT00961896 2015-11-03
A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients
Novartis
Phase 2 Completed
NCT01350115 2015-10-19
Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
Novartis
Phase 2 Completed